A major news story from Sanofi this month is that "The European Medicines Agency has approved Dupixent (dupilumab) to treat ...
Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals is hosting a webinar on November 15, 2024, focusing on Eosinophilic Esophagitis, a rapidly growing digestive ...
The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...
Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...
(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...
GlobalData on MSN6d
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trialA Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...
Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback